DataMeds Regains Compliance With NASDAQ Listing Standards

DataMeds AI (NASDAQ:MEDS) received a Nasdaq Compliance Notice dated October 19, 2026 confirming it has regained compliance with Listing Rule 5550(b)(1), the minimum stockholders' equity requirement of $2.5 million. The company had been in delisting proceedings since April 13, 2026 for failing both the $1.00 minimum bid-price and equity tests; bid-price compliance was restored June 9, 2026, and October 2026 Form 8-K filings confirmed stockholders' equity exceeded $2.5 million. Compliance is not fully durable: if the company fails to evidence compliance in its next periodic report, it may again face delisting.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.